Citicoline and Memory: Inside the Nakazaki Older-Adults Trial
Roon Team

Citicoline and Memory: Inside the Nakazaki Older-Adults Trial
If you want to understand whether a choline supplement actually does anything for an aging brain, the citicoline memory study led by Eri Nakazaki is the one to read. It is the trial people cite when they argue citicoline supports memory. It is also the trial people misread.
So here is the honest version. The 2021 paper tested 500 mg of citicoline per day, for 12 weeks, in healthy older adults with normal age-related memory decline. The headline result was real but specific, and the details matter more than the press release.
Key Takeaways
- The nakazaki citicoline trial ran 12 weeks in 100 adults aged 50 to 85 with age-associated memory impairment (AAMI).
- The group taking 500 mg of citicoline daily improved on episodic memory and a composite memory score more than the placebo group.
- The biggest effect showed up in a Paired Associates task, a test of learning new word and image links.
- Citicoline works by feeding the choline pathway your brain uses to build cell membranes and acetylcholine.
- This is a slow, structural story measured in weeks, not a same-day focus boost.
What the Citicoline Memory Study Actually Tested
The full citation is worth knowing. The study by Eri Nakazaki, Eunice Mah, Kristen Sanoshy, Danielle Citrolo, and Fumiko Watanabe appeared in The Journal of Nutrition in August 2021, volume 151, issue 8, pages 2153 to 2160. The supplement used was Cognizin, a branded form of citicoline.
The design was clean. A total of 100 healthy men and women aged between 50 and 85 with AAMI took part in a randomized, double-blind, placebo-controlled trial, randomized to receive either placebo or citicoline at 500 mg per day for 12 weeks. 99 out of 100 participants completed the study in full.
Two things stand out. First, these were healthy older adults, not patients with dementia or stroke. Earlier citicoline research had shown beneficial effects on memory in populations with a range of impairments, but few studies had looked at healthy older populations. Second, the dose was modest. This was reported as the first trial to study daily supplementation of 500 mg of citicoline and its effects.
Memory was measured with computerized tests from Cambridge Brain Sciences, taken at the start and again at the 12-week mark.
The Results: Episodic Memory Led the Way
The clearest win was in episodic memory. After the 12-week intervention, participants supplemented with citicoline showed markedly greater improvements in episodic memory, assessed by the Paired Associate test, compared with those on placebo, with mean changes of 0.15 versus 0.06 and a P value of 0.0025.
Episodic memory is the kind you use to recall events, names attached to faces, and where you put your keys. The Paired Associates task probes exactly that, your ability to learn and hold new associations.
The composite score backed it up. Composite memory, calculated using the scores of four memory tests, also markedly improved to a greater extent following citicoline supplementation, with a mean change of 3.78 versus 0.72 in placebo and a P value of 0.0052.
The authors were careful with their framing. They noted their study was the first to demonstrate a beneficial effect of citicoline supplementation in maintaining or improving episodic memory that may decline with age. The conclusion the team drew was equally measured. Dietary supplementation of citicoline for 12 weeks improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI, and the findings suggest that regular consumption may be safe and potentially beneficial against memory loss due to aging.
Note the word "may." This was a single, industry-sponsored trial, and the researchers wrote it that way on purpose.
Why Citicoline Might Affect Memory at All
Citicoline is not a stimulant. It is a building block. Citicoline increases the synthesis of phosphatidylcholine, the primary component of neuronal membranes, enhances acetylcholine synthesis, and promotes the synthesis of other membrane phospholipids.
Break that into plain terms. Phosphatidylcholine is structural material for the walls of your brain cells. Acetylcholine is a neurotransmitter tied to attention and memory formation. Citicoline feeds both pathways.
That mechanism explains the trial's design. You do not rebuild membrane phospholipids in an afternoon. You do it over weeks, which is why the study ran for 12 of them and measured the difference at the end, not the same day.
How This Trial Fits the Broader Evidence
One strong trial is a starting point, not a verdict. The most useful reality check came from European regulators.
In 2024, the EFSA Panel on Nutrition reviewed a proposed health claim linking citicoline to memory support in middle-aged and elderly adults. The Panel concluded that a cause-and-effect relationship had not been established between consumption of citicoline (CDP-Choline) inner salt and improvement, maintenance, or reduced loss of memory in middle-aged or elderly adults with age-associated subjective memory impairment. You can read the EFSA opinion summary on PubMed.
This is not a contradiction of the Nakazaki paper. It is a higher bar. EFSA wants converging evidence across multiple independent trials before it will authorize a claim, and that body of work is not there yet. The citicoline trial itself is open access on PMC if you want to judge the data for yourself.
Where the Nakazaki Trial Sits
| Question | What the trial showed | The caveat |
|---|---|---|
| Dose tested | 500 mg per day | Single dose level, no comparison arm at higher or lower doses |
| Duration | 12 weeks | No data on shorter or longer use |
| Population | Healthy adults 50 to 85 with AAMI | Not generalizable to younger or impaired groups |
| Strongest result | Episodic memory (Paired Associates) | Secondary outcome, single trial |
| Funding | Kyowa Hakko Bio (Cognizin maker) | Industry-sponsored |
| Regulatory status | N/A | EFSA found cause-and-effect not yet established |
What This Means If You Are Considering Citicoline
Treat the citicoline 500 mg memory result as a promising signal, not a settled fact. The trial was well run and the episodic memory effect was statistically clear, but it stands largely alone in healthy older adults.
If you do try citicoline, the study points to a few practical reads. The dose with evidence behind it is 500 mg daily. The timeline is patient, think 12 weeks before judging anything. And the benefit it was tied to is memory over time, not alertness in the moment.
For anyone curious how stacked stimulant compounds differ from a structural nutrient like this, our breakdown of how caffeine and L-theanine work together for focus covers the acute side of the cognitive equation.
The Bottom Line on the Nakazaki Trial
The Nakazaki trial is the strongest single piece of evidence that 500 mg of daily citicoline can support episodic memory in healthy older adults with age-related decline. The effect was real, statistically marked, and biologically plausible given how citicoline feeds the choline pathway.
It is also one trial, funded by the ingredient's maker, and not yet matched by the independent replication regulators want to see. Both of those statements are true at once. That is what honest reading of a landmark study looks like: take the result seriously, hold the certainty loosely, and watch for the next trial.
Frequently Asked Questions
What is the citicoline memory study by Nakazaki?
It is a 2021 randomized, double-blind, placebo-controlled trial published in The Journal of Nutrition. It enrolled 100 healthy adults aged 50 to 85 with age-associated memory impairment, who received either placebo or 500 mg of citicoline daily for 12 weeks. The citicoline group showed greater improvements in episodic and composite memory scores than placebo.
How much citicoline did the trial use?
500 mg per day. It was reported as the first trial to study daily supplementation of 500 mg of citicoline and its effects. The study did not test higher or lower doses, so 500 mg is the figure with direct evidence behind it in this population, not a proven optimum.
What is episodic memory and why did it improve?
Episodic memory is your recall of specific events, associations, and recently learned information. In the trial, the citicoline group improved more than placebo on the Paired Associate test, a measure of learning new pairings, with a P value of 0.0025. Citicoline supports the acetylcholine and membrane pathways involved in forming these memories.
How does citicoline work in the brain?
Citicoline increases synthesis of phosphatidylcholine, the main component of neuronal membranes, enhances acetylcholine synthesis, and promotes synthesis of other membrane phospholipids. In short, it supplies raw materials your brain uses to build cell membranes and a memory-related neurotransmitter, which is a slow structural process.
Is the citicoline memory evidence conclusive?
No. In 2024, the EFSA Panel concluded that a cause-and-effect relationship had not been established between citicoline and improvement, maintenance, or reduced loss of memory in middle-aged or elderly adults with age-associated subjective memory impairment. The Nakazaki trial is encouraging, but regulators want more independent replication.
How long does citicoline take to affect memory?
The trial measured results after 12 weeks of daily use. Because citicoline works by feeding membrane and neurotransmitter synthesis rather than acting as a stimulant, its memory-related effects are gradual. Expect to think in terms of months of consistent use, not hours, if you are basing decisions on this study.
Was the Cognizin trial independent?
Not fully. The research was sponsored by Kyowa Hakko Bio, a subsidiary of Japan's Kirin Group, which makes the Cognizin branded citicoline used in the study. The trial design was rigorous, but industry funding is a reason to wait for independent confirmation before treating the result as settled.
Memory Is a Choline-Pathway Story. Focus Is a Different One.
The Nakazaki trial is about a slow build: feeding the choline pathway over 12 weeks to support episodic memory as the brain ages. That is a worthwhile goal, and it is a different goal from feeling sharp in the next ten minutes.
Roon lives in that second lane. It is a sublingual pouch built for acute focus and reaction time, with a four-ingredient stack of 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine), designed for a 5 to 10 minute onset and 6 to 8 hours of steady focus with no jitters, no crash, and no tolerance buildup.
Roon is not a memory supplement and not a substitute for long-term choline support like citicoline. If you want clean, fast focus for a workday or a study block, try Roon, and keep the long-game memory work as its own separate habit.
Written by Roon Team






